CL2013002629A1 - Compuestos derivados de isoxazolidina; composicion y combinacion farmaceutica que los comprende, util para la prevencion y/o el tratamiento de las enfermedades relacionadas con la reduccion en la cantidad, la actividad o el movimiento de las celulas que participan en la inflamacion, enfermedades respiratorias, asma y epoc. - Google Patents
Compuestos derivados de isoxazolidina; composicion y combinacion farmaceutica que los comprende, util para la prevencion y/o el tratamiento de las enfermedades relacionadas con la reduccion en la cantidad, la actividad o el movimiento de las celulas que participan en la inflamacion, enfermedades respiratorias, asma y epoc.Info
- Publication number
- CL2013002629A1 CL2013002629A1 CL2013002629A CL2013002629A CL2013002629A1 CL 2013002629 A1 CL2013002629 A1 CL 2013002629A1 CL 2013002629 A CL2013002629 A CL 2013002629A CL 2013002629 A CL2013002629 A CL 2013002629A CL 2013002629 A1 CL2013002629 A1 CL 2013002629A1
- Authority
- CL
- Chile
- Prior art keywords
- activity
- isoxazolidine
- asthma
- inflammation
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPUESTOS QUÍMICOS DERIVADOS DE ISOXAZOLIDINA DE FÓRMULA GENERAL (IN) QUE PRESENTAN ACTIVIDAD ANTIINFLAMATORIA Y ANTIALÉRGICA; COMPOSICION Y COMBINACION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA LA PREVENCION Y/O EL TRATAMIENTO DE LAS ENFERMEDADES RELACIONADAS CON LA REDUCCION EN LA CANTIDAD, LA ACTIVIDAD O EL MOVIMIENTO DE LAS CELULAS QUE PARTICIPAN EN LA INFLAMACION, ENFERMEDADES RESPIRATORIAS, ASMA Y EPOC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11158230 | 2011-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013002629A1 true CL2013002629A1 (es) | 2014-01-10 |
Family
ID=44351355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002629A CL2013002629A1 (es) | 2011-03-15 | 2013-09-12 | Compuestos derivados de isoxazolidina; composicion y combinacion farmaceutica que los comprende, util para la prevencion y/o el tratamiento de las enfermedades relacionadas con la reduccion en la cantidad, la actividad o el movimiento de las celulas que participan en la inflamacion, enfermedades respiratorias, asma y epoc. |
Country Status (22)
Country | Link |
---|---|
US (3) | US20120234316A1 (es) |
EP (2) | EP2716648B1 (es) |
JP (1) | JP6053700B2 (es) |
KR (1) | KR101956937B1 (es) |
CN (1) | CN103391945B (es) |
AR (1) | AR085817A1 (es) |
AU (1) | AU2012228334B2 (es) |
BR (1) | BR112013023539B1 (es) |
CA (1) | CA2850081C (es) |
CL (1) | CL2013002629A1 (es) |
EA (1) | EA028904B1 (es) |
GE (1) | GEP201606566B (es) |
IL (1) | IL228382A (es) |
MX (1) | MX345400B (es) |
MY (1) | MY194140A (es) |
PE (1) | PE20140890A1 (es) |
SG (1) | SG193262A1 (es) |
TN (1) | TN2013000313A1 (es) |
TW (1) | TWI658047B (es) |
UA (1) | UA113508C2 (es) |
WO (1) | WO2012123482A2 (es) |
ZA (2) | ZA201306881B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2739640A1 (en) | 2011-08-01 | 2014-06-11 | Chiesi Farmaceutici S.p.A. | Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring |
US9155747B2 (en) * | 2012-09-13 | 2015-10-13 | Chiesi Farmaceutici S.P.A. | Isoxazolidine derivatives |
EP2902382A1 (en) * | 2014-01-30 | 2015-08-05 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Primary hydroxylamines and uses thereof |
US10239877B2 (en) * | 2014-03-31 | 2019-03-26 | The Scripps Research Institute | Pharmacophore for trail induction |
RS60450B1 (sr) | 2014-09-03 | 2020-07-31 | Rhizen Pharmaceuticals Sa | Postupak za tretiranje i kompozicije koje sadrže dvojni inhibitor pi3k delta-gama kinaze i kortikosteroid |
CN104262440B (zh) * | 2014-09-10 | 2016-08-17 | 江西赣亮医药原料有限公司 | 一种16ɑ-羟基泼尼松龙的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31997A (en) * | 1968-05-03 | 1974-03-14 | Lepetit Spa | Process for the preparation of pregnano(17alpha,16alpha-d)oxazolines and 16alpha,21-dihydroxy-17alpha-aminopregnanes |
US4018774A (en) | 1976-02-13 | 1977-04-19 | E. R. Squibb & Sons, Inc. | Steroidal [16α,17-d]isoxazolidines |
PT69410A (fr) * | 1978-04-05 | 1979-04-01 | Syntex Inc | Process pour preparation de 4-6-dihalo steroids |
WO2005028495A1 (en) * | 2003-09-24 | 2005-03-31 | Glaxo Group Limited | Anti-inflammatory glucocorticoids |
GB0415747D0 (en) * | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CN101287369A (zh) | 2005-01-03 | 2008-10-15 | 美瑞德生物工程公司 | 治疗脑癌的方法 |
EA201070535A1 (ru) * | 2007-11-30 | 2010-12-30 | Пфайзер Лимитед | Новые агонисты глюкокортикоидных рецепторов |
JP2011513303A (ja) * | 2008-02-27 | 2011-04-28 | アストラゼネカ・アクチエボラーグ | 16アルファ,17アルファ−アセタールグルココルチコステロイド誘導体およびその使用 |
CN101926805A (zh) * | 2009-06-24 | 2010-12-29 | 天津金耀集团有限公司 | 一种含有16,17异恶唑烷类甾体化合物的药物组合物 |
CN105175479B (zh) | 2009-09-11 | 2017-06-09 | 奇斯药制品公司 | 异噁唑烷衍生物 |
TW201139369A (en) * | 2010-02-05 | 2011-11-16 | Chiesi Farma Spa | Pyrrolidine derivatives |
BR112013022890A2 (pt) | 2011-03-15 | 2016-09-13 | Chiesi Farma Spa | composto, composição farmacêutica, combinação e uso de um composto |
EP2739640A1 (en) | 2011-08-01 | 2014-06-11 | Chiesi Farmaceutici S.p.A. | Anti -inflammatory steroids condensed in position 16,17 with pyrrolidine ring |
US9155747B2 (en) | 2012-09-13 | 2015-10-13 | Chiesi Farmaceutici S.P.A. | Isoxazolidine derivatives |
-
2012
- 2012-03-14 JP JP2013558416A patent/JP6053700B2/ja not_active Expired - Fee Related
- 2012-03-14 AU AU2012228334A patent/AU2012228334B2/en not_active Ceased
- 2012-03-14 CA CA2850081A patent/CA2850081C/en active Active
- 2012-03-14 MY MYPI2013002925A patent/MY194140A/en unknown
- 2012-03-14 AR ARP120100843A patent/AR085817A1/es active IP Right Grant
- 2012-03-14 KR KR1020137022976A patent/KR101956937B1/ko active IP Right Grant
- 2012-03-14 BR BR112013023539-0A patent/BR112013023539B1/pt not_active IP Right Cessation
- 2012-03-14 CN CN201280008928.3A patent/CN103391945B/zh not_active Expired - Fee Related
- 2012-03-14 SG SG2013065974A patent/SG193262A1/en unknown
- 2012-03-14 TW TW101108588A patent/TWI658047B/zh not_active IP Right Cessation
- 2012-03-14 EA EA201391173A patent/EA028904B1/ru not_active IP Right Cessation
- 2012-03-14 WO PCT/EP2012/054439 patent/WO2012123482A2/en active Application Filing
- 2012-03-14 UA UAA201310933A patent/UA113508C2/uk unknown
- 2012-03-14 EP EP13197855.3A patent/EP2716648B1/en active Active
- 2012-03-14 GE GEAP201213223A patent/GEP201606566B/en unknown
- 2012-03-14 EP EP12711601.0A patent/EP2686332A2/en not_active Withdrawn
- 2012-03-14 PE PE2013002015A patent/PE20140890A1/es active IP Right Grant
- 2012-03-14 MX MX2013010354A patent/MX345400B/es active IP Right Grant
- 2012-03-15 US US13/421,150 patent/US20120234316A1/en not_active Abandoned
-
2013
- 2013-07-24 TN TNP2013000313A patent/TN2013000313A1/fr unknown
- 2013-09-12 CL CL2013002629A patent/CL2013002629A1/es unknown
- 2013-09-12 ZA ZA2013/06881A patent/ZA201306881B/en unknown
- 2013-09-12 IL IL228382A patent/IL228382A/en active IP Right Grant
-
2014
- 2014-07-31 ZA ZA2014/05681A patent/ZA201405681B/en unknown
- 2014-11-10 US US14/537,184 patent/US9845337B2/en active Active
-
2017
- 2017-11-08 US US15/807,066 patent/US10280193B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
CY1116315T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
CL2013002629A1 (es) | Compuestos derivados de isoxazolidina; composicion y combinacion farmaceutica que los comprende, util para la prevencion y/o el tratamiento de las enfermedades relacionadas con la reduccion en la cantidad, la actividad o el movimiento de las celulas que participan en la inflamacion, enfermedades respiratorias, asma y epoc. | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112014014809A2 (pt) | composições farmacêuticas compreendendo glitazonas e ativadores de nrf2 | |
ECSP13012967A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PH12015501385A1 (en) | Autotaxin inhibitors | |
BR112015029970A2 (pt) | inibidores de cinase | |
NZ708593A (en) | Novel pyrazole derivative | |
CR20130487A (es) | 1,3-oxazinas como inhibidores de BACE1 y/o BACE2 | |
CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
CL2012003722A1 (es) | Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida. | |
UY29079A1 (es) | Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази | |
CO6690805A2 (es) | 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3 | |
TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer |